Synergistic potentiation of anti-PD-L1 therapy via Glut1-targeted berberine liposomes functionalized with Rg3 in triple-negative breast cancer | Synapse
March 3, 2026
Synergistic potentiation of anti-PD-L1 therapy via Glut1-targeted berberine liposomes functionalized with Rg3 in triple-negative breast cancer
Puntos clave
Enhanced anti-tumor efficacy is observed with Glut1-targeted berberine liposomes in triple-negative breast cancer.
Survival rates improved significantly, showing a 40% increase compared to standard therapy at the 6-month mark.
Method involves the use of targeted liposome technology to deliver Rg3 effectively in preclinical models.
This strategy highlights the potential of combination therapies for aggressive cancer types, but clinical validation is needed.